Literature DB >> 27825460

Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.

Shahrzad Jalali1, Stephen M Ansell2.   

Abstract

Waldenstrom Macroglobulinemia (WM) is a low-grade B-cell lymphoma defined firstly by infiltration of lymphoplasmacytic cells into the bone marrow (BM), the milieu where the cells acquire signals that promote malignant growth and proliferation. A second characteristic associated with WM is the increased synthesis of monoclonal immunoglobulin M (IgM) by lymphoplasmacytic cells, which is secreted in the serum and often results in hyperviscosity. Advanced genomic tools have improved our understanding of the genetic events that contribute to malignant transformation in WM, but the role of BM microenvironment is also emerging as having an essential role in WM disease progression. Therefore, delineation of malignant WM cell growth in the context of its microenvironment would benefit the design of more efficient therapeutic strategies. Here, we highlight available data regarding the interaction of the WM cells with the cellular and non-cellular compartments of the BM and discuss how BM provides a permissive environment for WM cell growth and proliferation.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Waldenstrom Macroglobulinemia

Mesh:

Substances:

Year:  2016        PMID: 27825460     DOI: 10.1016/j.beha.2016.08.016

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  5 in total

1.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

2.  Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

Authors:  Stephan J Matissek; Weiguo Han; Mona Karbalivand; Mohamed Sayed; Brendan M Reilly; Shayna Mallat; Shimaa M Ghazal; Manit Munshi; Guang Yang; Steven P Treon; Sarah R Walker; Sherine F Elsawa
Journal:  Epigenomics       Date:  2020-12-24       Impact factor: 4.778

3.  Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.

Authors:  Nagham Alouche; Amélie Bonaud; Vincent Rondeau; Rim Hussein-Agha; Julie Nguyen; Valeria Bisio; Mélanie Khamyath; Etienne Crickx; Niclas Setterblad; Nicolas Dulphy; Matthieu Mahevas; David H McDermott; Philip M Murphy; Karl Balabanian; Marion Espéli
Journal:  Blood       Date:  2021-06-03       Impact factor: 25.476

4.  Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia.

Authors:  Weiguo Han; Stephan J Matissek; David A Jackson; Brandon Sklavanitis; Sherine F Elsawa
Journal:  Oncotarget       Date:  2019-05-21

Review 5.  Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.

Authors:  Daniela Drandi; Philippe Decruyenaere; Martina Ferrante; Fritz Offner; Jo Vandesompele; Simone Ferrero
Journal:  Diagnostics (Basel)       Date:  2022-04-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.